Global footprint Porton operates across the United States, Europe, and China, with a global network of development and manufacturing facilities. This regional presence supports multi-region programs, streamlined regulatory readiness, and resilient supply chains for biotech and pharmaceutical partners seeking global reach.

End-to-end platforms Offers end-to-end capabilities from discovery through GMP manufacturing across small molecules, Tides, biologics and conjugates (ADCs, AOCs, PDCs, RDCs) and advanced therapy products, enabling a single partner to manage complex programs and reduce handoffs and timelines.

Capacity expansion Recent investments and facility expansions signal strong capacity to scale with client programs: significant asset investments in 2022, a state-of-the-art small-molecule platform launched in Shanghai in 2023, and expansion of facilities including Cranbury, New Jersey; collaboration activity such as the Slovenian site development with Novartis demonstrates multi-site scalability.

Quality and sustainability Porton has been recognized for process innovation, supply chain performance, and compliance with global quality and environmental, health, and safety standards, reinforcing risk management and reliability for regulated programs and long-term partnerships. It also received a nomination for the Positive Endeavors Award at the 2025 Sedex Supply Chain Award Ceremony.

Strategic partnerships With experience collaborating with major pharma players including Novartis and a global footprint, Porton is positioned to win multi-regional CDMO partnerships, particularly for programs requiring complex modalities, speed to clinic, and advanced therapy support.